US pharma giant Pfizer's new bivalent mRNA-based Covid booster vaccine has shown to be highly effec…

"What this study contributes with is the longer follow-up time and the fact that we were able to e…

One in eight adults who are infected with the SARS-CoV-2 virus experience long term symptoms due to…

Moreover, when global manufacturers were concentrating on producing vaccines China was busy de…

"There is still much work to be done before we can confirm if our vaccine will help manage the…

Russia's Sputnik V vaccine demonstrated efficacy of 91.6 per cent against Covid-19, according to in…

Amid heated debates on whether people should be told to get booster shots of vaccine, in the face o…

One in four people experience mild, short lived systemic side effects like headache, fatigue and te…

A previous clinical trial reported similar results for a different vaccine that is also based on…

A"The efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic…

The results of an interim study recently published in The Lancet showed that two doses of Covaxi…

These are Business Insider's biggest healthcare stories for December 9.

Covaxin had initially raised concerns among experts over its emergency approval by India's dr…

Instead of moralizing the issue, we should seek to understand the reasons and circumstances that ha…

"When we looked at the effectiveness of the two doses of Pfizer–BioNTech vaccine versus three dose…

On May 1, as the country opens up its vaccination drive to everyone above the age of 18 years, 600 …